| (Values in U.S. Thousands) | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 | Mar, 2021 |
| Sales | 10 | 10 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,430 | -2,390 | -760 | -240 | -6,000 |
| Net Income Growth | -1.67% | -214.47% | -216.67% | +96.00% | -990.91% |
Amorfix Life Science (ARFXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.